Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2007-08-20
2010-12-28
Reddig, Peter J (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C530S326000, C514S002600, C514S013800
Reexamination Certificate
active
07858738
ABSTRACT:
Synthetic peptides of at least 12 and at most 30 amino acid residues comprising a sequence consisting of, or found within, a complementarity-determining region (CDR) found in the heavy or light chain of the human anti-DNA 16/6Id monoclonal antibody, or a sequence obtained by replacement and/or deletion and/or addition of one or more amino residues to said sequence, and salts, chemical derivatives and polymers of said peptides can be used for immunomodulation of systemic lupus erythematosus-associated responses.
REFERENCES:
patent: 4656158 (1987-04-01), Matsuo et al.
patent: 5126249 (1992-06-01), Becker et al.
patent: 5134127 (1992-07-01), Stella et al.
patent: 5356779 (1994-10-01), Mozes et al.
patent: 5376645 (1994-12-01), Stella et al.
patent: 5646131 (1997-07-01), Badwan et al.
patent: 5730969 (1998-03-01), Hora et al.
patent: 5997856 (1999-12-01), Hora et al.
patent: 6066621 (2000-05-01), Sela et al.
patent: 6228363 (2001-05-01), Naparstek
patent: 6407079 (2002-06-01), Muller et al.
patent: 6613536 (2003-09-01), Mozes et al.
patent: 7294687 (2007-11-01), Cohen-Vered et al.
patent: 2002/0054872 (2002-05-01), Naparstek
patent: 2003/0105000 (2003-06-01), Pero et al.
patent: 2004/0127408 (2004-07-01), Mozes et al.
patent: 2004/0180059 (2004-09-01), Cohen-Vered et al.
patent: 2005/0008634 (2005-01-01), Cohen-Vered et al.
patent: 0495049 (1992-07-01), None
patent: 9630057 (1996-10-01), None
patent: 9931066 (1999-06-01), None
patent: 02067848 (2002-09-01), None
patent: 2004064787 (2004-08-01), None
patent: 2004064788 (2004-08-01), None
Ibragimova and Eade (Biophysical Journal, Oct. 1999, vol. 77, pp. 2191-2198).
Burgess et al (J of Cell Bio. 111:2129-2138, 1990).
Scott et al (Nature Genetics, 1999, 21:440-443).
Berg et al. (Biochemistry, 5th ed., W. H. Freeman and Co. 2002, section 3.2).
Lazar et al (Molecular and Cellular Biology, 1988, 8:1247-1252).
Anderson, B.D. et al. (1996), “The Practice of Medicinal Chemistry”Academic Press34:739-754.
Audibert et al. (1981) Active antitoxic immunization by a diphtheria toxin synthetic oligopeptide.Nature, 289:593-4.
Axelrod, O. and Mozes, E. (1986) Analysis of the biological functions and fine specificity of (T,G)-A—L specific T cell clones.Immunobiology, 172:99-109.
Bombardier C. et al. (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.Arthritis Rheum., 35:630-40.
Brosch N. et al. (2000) A Peptide Based on the Sequence of the CDR3 of a Murine Anti-DNA mAb is a Better Modulator of Experimental SLE than its Single Amino Acid-Substituted Analogs.Cellular Immunology, 205:52-61.
Brosch N. et al. (2000) Characterization and Role in Experimental Systemic Lupus Erythematosus of T-cell Lines Specific to Peptides Based on Complementarity-Determining Region-1 and Complementarity-Determining Region-3 of a Pathogenic Anti-DNA Monoclonal Antibody.Immunology99:257-264.
Conlon, P.J. (1983) A rapid biologic assay for the detection of interleukin 1.J. Immunol., 134:1280-2.
Dayan M. et al. (2000) Immune response of SLE patients to peptides based on the complementarity determining regions of a pathogenic anti-DNA monoclonal antibody.J. Clin. Immunol.,20(3):187-94.
Dean G.S. et al. (2000) Cytokines and systemic lupus erythematosus.Ann. Rheum. Dis., 59:243-51.
Eilat, E., et al. (2000) Prevention of systemic lupus erythematosus-like disease in (NZBxNZW)F1 mice by treating with CDR1- and CDR3- based peptides of pathogenic autoantibody.J. Clin. Immunol., 20:268-78.
U.S. Appl. No. 10/758,572, filed Jan. 14, 2004.
U.S. Appl. No. 11/985,068, filed Jan. 14, 2004.
Eilat, E., et al. (2001) The mechanism by which a peptide based on complementarity determining region-1 of pathogenic anti-DNA antibody ameliorates experimental SLE.Proc. Natl. Acad. Sci. U.S.A., 98: 1148-53.
Fricke, H. et al. (1991) Idiotype specific T-cell lines inducing experimental systemic lupus erythematosus in mice.Immunology, 73:421-7.
Fricke, H. et al. (1990) Induction of experimental systemic lupus erythematosus in mice by immunization with a monoclonal anti-La autoantibody.Int. Immunol., 2:225-30.
Gearing, A.J.H. et al. (1994) Processing of tumor necrosis factor-alpha precursor by metalloproteinases.Nature, 370:555-7.
Gijbels, K. et al. (1992) Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders.J. Neuroimmunol., 41:29-34.
Goetzl, E.J. et al. (1996) Matrix metalloproteinases in immunity.J. Immunol., 156:1-4.
Guedez, L. et al. (1996) The role of metalloproteinases and their inhibitors in hematological disorders.Crit. Rev. Oncog., 7:205-25.
Hay, E.M. et al. (1993) The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.Q. J. Med., 86:447-58.
Isenberg, D.A., et al. (1984) Anti-DNA antibody idiotypes in systemic lupus erythematosus.Lancet, 2(8400):417-22.
Isenberg, D.A., et al. (1985) Detection of cross-reactive anti-DNA antibody idiotypes on renal tissue-bound immunoglobulins from lupus patients.J. Clin. Invest., 76(1):287-94.
Katchalski, E. et al. (1955) Molecular weight distribution of linear and multichain polyamino acids. Statistical analysis.J. Am. Chem. Soc., 77:6175-82.
Kotajima, L., et al., (1998) Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis.Clin. Exp. Rheumatol., 16(4):409-15.
Mendlovic, S. et al. (1988) Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype.Proc. Natl. Acad. Sci. U.S.A., 85:2260-4.
Mendlovic, S. et al. (1989) The role of anti-idiotypic antibodies in the induction of experimental systemic lupus erythematosus in mice.Eur. J. Immunol., 19:729-34.
Mendlovic, S. et al. (1990) The genetic regulation of the induction of experimental SLE.Immunology, 69:228-36.
Mozes, E. et al. (1989) Direct binding of a myasthenia gravis related epitope to MHC class II molecules on living murine antigen-presenting cells.EMBO J., 8:4049-52.
Muller, G.M. et al. (1982) Anti-influenza response achieved by immunization with a synthetic conjugate.Proc. Natl. Acad. Sci. U.S.A., 79:569-73.
Nakamura, T. et al. (1993) Gene expression of metalloproteinases and their inhibitor in renal tissue of New Zealand black/white F1 mice.Clin. Sci., 85:295-301.
Naparstek, Y. et al. (1989) Sequential Anti-Idiotypes Define Reciprocal Idiotopes on the Same Anti-DNA Antibody.Clinical Immunology and Immunopathology, 50:S106-S116.
Paemen, L. et al. (1994) Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases.Eur. J. Neurol., 1:55-63.
Ruiz, P.J. et al. (1994) Induction of experimental systemic lupus erythematosus in mice by immunization with the F(ab′)2 fragment of the human anti-DNA monoclonal antibody carrying the 16/6 idiotype.Immunol. Lett., 41:79-84.
Saren, P. et al. (1996) TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages.J. Immunol., 157:4159-65.
Schnolzer, M. et al. (1992) In situ neutralization in Boc-chemistry solid phase synthesis. Rapid, High yield assembly of difficult sequences. Int. J. Pept. Protein Res., 40: 180-93.
Segal, R. et al. (1997) Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1/T helper cell 2-type cytokines in disease.J. Immunol., 158:3009-16.
Shoenfeld, Y. et al. (1983) Idiotypic cross-reactions of monoclonal human lupus autoantibodies.J. Exp. Med., 158:718-30.
Shoenfeld, Y. et al. (1982) Production of autoantibodies by human-human hybridomas.J. Clin. Invest., 70:205-8.
Sthoeger, Z.M. et al. (1993) Monoclonal anticardiolipin antibodies derived from mice with experimental lupus erythematosus: characterization and the induction of a secondary antiphospholipid syndrome.J. Clin. Immunol., 13:127-38.
Tan, E.M. et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus.Arthritis Rheum., 25:1271-7.
Theofilopoulos, A.N. et al. (1999) Tumour ne
Cooper & Dunham LLP
Reddig Peter J
White John P.
Yeda Research and Development Co. Ltd.
LandOfFree
Synthetic human peptides and pharmaceutical compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic human peptides and pharmaceutical compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic human peptides and pharmaceutical compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4171704